Rapid, potent and durable viral
suppression, with fewer
medicines vs. 3DRs[1–3]

DOVATO is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.[3]

RCT data    RWE data

Start and stay strong with DOVATO[2]

Rapid, potent and durable viral suppression through ~3 years of follow up[2]

DOVATO demonstrated non-inferior efficacy vs. DTG + TDF/FTC through 144 weeks in treatment-naïve participants[2]

Primary endpoint: proportion of participants with plasma viral load <50 copies/mL at Week 48 (ITT-E population, FDA Snapshot analysis).[2]

Proven long-term effectiveness, from diagnosis[5]

CoRIS is an open, multicentre, prospective cohort study of people naïve to treatment living with HIV conducted across 48 participating centres in Spain from 2018 to 2021.[5]

DOVATO showed comparable virological outcomes to 3/4DRs including BIC/FTC/TAF at 96 weeks (ITT analysis)[5]

Adapted from Suárez-García I et al. 2025.[5]

Primary outcomes: the proportion of participants achieving HIV-RNA <50 copies/mL at 96 (±24) weeks after initiation of ART and the rates of virological failure after viral suppression.†,[5]

The confidence of a proven high barrier to resistance[1–3]

Discover barrier to resistance

A well-established safety profile[3]

Explore safety data

*DTG 50 mg + 3TC 300 mg were used in the GEMINI I and II studies.[2]
†Virological failure after viral suppression was defined as two consecutive HIV RNA viral load levels >50 copies/mL or one >1,000 copies/mL after virological failure and prior to 96 weeks after initiation.[5]

3DR, 3-drug regimen; 3/4DR, 3- or 4-drug regimen; 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; BIC, bictegravir; CI, confidence interval; COBI, cobicistat; DTG, dolutegravir; DRV, darunavir; FDA, United States Food and Drug Administration; FTC, emtricitabine; HBV, hepatitis B virus; ITT, intention-to-treat; ITT-E, intention-to-treat-exposed; RCT, randomised controlled trial; RWE, real-world evidence; SD, standard deviation; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

References:

  1. Figueroa M et al. Clin Infect Dis 2025. https://doi.org/10.1093/cid/ciaf415. [Epub ahead of print].
  2. Cahn P et al. AIDS 2022; 36(1): 39–48.
  3. DOVATO (dolutegravir/lamivudine) Summary of Product Characteristics (SmPC).
  4. Cahn P et al. Lancet 2019; 393(10167): 143–155.
  5. Suárez-García I et al. J Antimicrob Chemother 2025; 80(3): 682–691.

PM-GB-DLL-WCNT-250005 | February 2026

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.